Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

What Was Tested

This randomized controlled trial paper looks at Glucagon and Amylin (Islet Amyloid Polypeptide).

The researchers investigated whether the effects of GLP-1 on gastric emptying, appetite, and food intake are mediated directly or indirectly via release of amylin.

Who Took Part

PubMed indexes the participants as adults.

Eleven C-peptide and amylin-negative patients with type 1 diabetes mellitus (T1DM) and 12 matched healthy controls participated in a placebo-controlled, randomized, single-blinded, crossover study.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether Glucagon was given.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

With glucose clamped between 6 and 9 mm, near-physiological infusions of GLP-1, human amylin, pramlintide, or saline were given for 270 min during and after a fixed meal.

Gastric emptying was measured using paracetamol, appetite using visual analog scales, and food intake during a subsequent ad libitum meal (at 240 min).

What Was Measured

PubMed files the paper under topics including Amyloid, Appetite, Body Mass Index, C-Peptide, Diabetes Mellitus, Type 1, Gastric Emptying and Glucagon.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Glucagon and Amylin (Islet Amyloid Polypeptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page and the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.